Canvi Behavioral Health Layton

Teen depression impacts millions of families each year. For some adolescents, traditional antidepressant treatment may not provide adequate relief.​

NeuroStar® Advanced Therapy is an FDA-cleared, non-invasive adjunct treatment option for adolescents ages 15–21 with major depressive disorder. Clinical data show meaningful improvement and remission rates in teens treated with NeuroStar.*​

If you are exploring options for a teen in your life, schedule a consultation to learn more.



*FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ± 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. “Measurable relief” was defined as a CGI-S score ≤3 and “complete remission” was defined as a CGI-S
score ≤2 at the end of treatment.

After treatment, Carmen noticed meaningful changes, not just in her mood, but in how she shows up for herself and her family. From exercising again to feeling more stable and present, she describes it simply: “My light is back.”

For those still searching for relief, Carmen’s experience offers hope and a reason to explore new options. NeuroStar may be an option for you or a loved one. Schedule a consultation to learn more.